A small case-control study found potential molecular evidence that links human papillomavirus (HPV) to thyroid eye disease (TED). A homology analysis of 11 patients with TED and 11 controls pinpointed ...

Luxturna, a treatment for LCA caused by mutations in the RPE65 gene, was the first gene therapy approved in the US in 2017 for a genetic disease. To the FDA ... another company developing treatments ...

With its lead program, Merida is targeting Graves’ disease, an autoimmune disorder that attacks the thyroid. The condition is characterized by autoantibodies binding to thyroid-stimulating hormone ...

During the active phase of TED, some patients present with mild symptoms (soft tissue involvement and lid retraction) and others with more serious ocular complications, such as proptosis (exophthalmos ...

Introduction: Graves´ disease (GD) is the predominant cause of hyperthyroidism. Treatment options include antithyroid drugs (ATD), surgery, and radioactive iodine ablation (RI). Although thyroid ...

Bugleweed is believed to act against the antibodies that cause Graves' disease, but it is not clear why it may reduce symptoms of hyperthyroidism even if you do not have this particular type.

Per draft FDA dry eye disease guidance, to be considered for regulatory approval in the United States, efficacy in dry eye disease may be demonstrated with two symptom trials and two sign trials.

Graves disease had a similar phenotype at presentation but a more severe clinical course when isolated than when part of autoimmune polyglandular syndrome. Despite similarities in biochemical and ...

This suggests that other environmental or genetic factors may contribute to the risk. Graves' disease is an autoimmune disorder in which the immune system attacks the thyroid gland, leading to the ...